capecitabine + cyclophosphamide + methotrexate

This is a combination chemotherapy regimen used primarily in the treatment of metastatic breast cancer. The regimen substitutes capecitabine for 5-fluorouracil (5-FU) in the classic CMF (cyclophosphamide, methotrexate, fluorouracil) protocol. Capecitabine is an oral prodrug that mimics continuous infusion of 5-FU and is converted to its active form preferentially within tumor cells. Cyclophosphamide is an alkylating agent that interferes with DNA replication, while methotrexate is an antimetabolite that inhibits DNA synthesis and repair[1][3]. The combination has shown feasibility and activity in clinical studies for advanced breast cancer[1].

Other names

cyclophosphamide/methotrexate/capecitabineCMX